Status:
UNKNOWN
A Survival Observational Study in Patients With Advanced IIIB-IV Squamous Cell Lung Cancer Receiving PD-1 Combination With Chemotherapy
Lead Sponsor:
Guangdong Association of Clinical Trials
Conditions:
Lung Squamous Cell Carcinoma Stage IV
Eligibility:
All Genders
18+ years
Brief Summary
This is a multi-center, open-label, non-interventional, retrospective registry study, with no pre-set statistical assumptions and will not intervene subject's clinical treatment or clinical management...
Eligibility Criteria
Inclusion
- Men and woman, aged over 18
- Cytology or histologically confirmed squamous cell lung cancer
- Advanced squamous cell lung cancer, Stage IIIb to IV according to AJCC staging (version 8)
- Patients receiving approved PD-1 mAb in combination with chemotherapy according to their condition
- Patients receiving PD-1 mAb in combination with chemotherapy for at least one cycle (21 days)
- Have imaging results with measurable tumor 2 weeks before receiving PD-1 mAb in combination with chemotherapy
- Able to understand and comply with the requirements of the consent and voluntarily participate in the study
Exclusion
- Patients participating in other clinical studies
- Severe medical data missing
- Unable to understand the purpose of the study or not agree with the requirement of the study
- Malignancies other than squamous cell lung cancer, history of malignancies
- Unsuitable for the study according to investigator
Key Trial Info
Start Date :
March 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2022
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT04306042
Start Date
March 1 2020
End Date
December 1 2022
Last Update
March 12 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China, 510080